FDA Tells Celera KIF6 Test Unapprovable Without Changes | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – The US Food and Drug Administration has told Celera that its application for pre-market approval of its KIF6 Genotyping Assay is not approvable "without major amendment," Celera disclosed after the close of the market on Wednesday.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: genetic study of breast cancer in Egyptian families, mutations linked to cleft lip and palate, and more.

Council Bluffs, Iowa, schools are encouraging more girls to pursue STEM courses, according to the Associated Press.

Because of new open-access requirements, Gates Foundation-funded researchers can't publish in some top journals, Nature News reports.

In Science this week: deletion of one microRNA allows pluripotent stem cells to form embryonic and non-embryonic lineages, and more.